We provide you with 20 years of free, institutional-grade data for PLRX stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of PLRX. Explore the full financial landscape of PLRX stock.
| Reported Date | CIK | Ticker | Type |
|---|
Pliant Therapeutics, Inc(NASDAQ:PLRX) 
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of av6 and ...
Website: http://www.pliantrx.com
Founded: 2015
Full Time Employees: 70
CEO: Bernard Coulie
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report about PLRX stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.